Deals being struck in the pharma sector could turn out to be a welcome boost for investors, but weighing up the risk is key.
A significant level of merger and acquisition (M&A) activity in the pharma sector is likely to pique investor interest, and leave them considering the role that pharma stocks should play in their investment portfolio.
Last week saw Dublin-based Actavis Plc, a major generic drug maker, agree to buy Forest...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team